1-11 of 11
Esther Mena
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Roshani Patel, Amrit Bhaskarla, Max J Gordon, Michael Emanuel, Dana I. Delgado Colon, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nick Micheletti, Laura M Yee, Nisha Patel, Irina Maric, Raul C. Braylan, Katherine R. Calvo, Louis M. Staudt, Ryan M. Young, Mark Roschewski, Dickran Kazandjian, Elizabeth Hill
Journal: Blood
Blood (2024) 144 (Supplement 1): 7059.
https://doi.org/10.1182/blood-2024-201563
Published: 2024
Journal Articles

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Allison Graeter, Christopher Melani, Max J Gordon, Jagan R. Muppidi, Sam Y. Ng, Sumaya Berg, Sarah Evans, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Bonita Bryant, Yandan Yang, Theresa Davies-Hill, Liza Lindenberg, Mark Ahlman, Esther Mena, Ethan Bergvall, Nick Micheletti, Laura M Yee, Allison P. Jacob, Monica Gallucci, Heidi Simmons, Alexander Bagaev, Mark Meerson, Ekaterina Postovalova, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2024) 144 (Supplement 1): 2958.
https://doi.org/10.1182/blood-2024-201711
Published: 2024
Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Elizabeth Hill, Joseph L. Roswarski, Amrit Bhaskarla, Alexander Dew, Candis Morrison, Michael Emanuel, Ani Petrosyan, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nisha Patel, Irina Maric, Alina Dulau-Florea, Katherine Calvo, Raul C. Braylan, Maryalice Stetler-Stevenson, Seth M. Steinberg, William Figg, Ryan M. Young, Ola Landgren, Mark Roschewski, Dickran Kazandjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 337.
https://doi.org/10.1182/blood-2023-181811
Published: 2023
Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, Christopher Melani, Jagan R. Muppidi, Stefania Pittaluga, James D Phelan, Colleen Ramsower, Lisa M. Rimsza, Ryan S Robertorye, George Wright, Mark Meerson, Ekaterina Postovalova, Alexander Bagaev, Nathan Fowler, Liza Lindenberg, Esther Mena, Ethan Bergvall, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Sumaya Berg, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2023-185038
Published: 2023
Journal Articles

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

Mark Roschewski, Liza Lindenberg, Esther Mena, Rahul Lakhotia, Christopher Melani, Seth M. Steinberg, Andre Schultz, Gregory Hogan, Jake J. Chabon, Sandra Close, Maximilian Diehn, Brian J. Sworder, David M. Kurtz, Ash A. Alizadeh, Wyndham H. Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 192.
https://doi.org/10.1182/blood-2023-180007
Published: 2023
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136182
Published: 2020
Journal Articles

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Elizabeth Hill, MD, Baris Turkbey, MD, Evrim Turkbey, MD, Candis Morrison, CNP, PhD, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-136185
Published: 2020
Journal Articles

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation

Brief Report
Nancy M. Hardy, Vicki Fellowes, Jeremy J. Rose, Jeanne Odom, Stefania Pittaluga, Seth M. Steinberg, Bazetta Blacklock-Schuver, Daniele N. Avila, Sarfraz Memon, Roger J. Kurlander, Hahn M. Khuu, Maryalice Stetler-Stevenson, Esther Mena, Andrew J. Dwyer, Bruce L. Levine, Carl H. June, Ran Reshef, Robert H. Vonderheide, Ronald E. Gress, Daniel H. Fowler, Frances T. Hakim, Michael R. Bishop
Journal: Blood
Blood (2012) 119 (12): 2956–2959.
https://doi.org/10.1182/blood-2011-09-378398
Published: 2012
Includes: Supplemental data
Journal Articles

Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study

Esther Tan, MD, Liza Lindenberg, MD, Neha Korde, MD, Alexandra Berg, Esther Mena, MD, Baris Turkbey, MD, Omer Aras, MD, Seth M. Steinberg, PhD, Brendan Weiss, MD, Alex Minter, MD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Peter Choyke, MD, Karen Kurdziel, MD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2888.
https://doi.org/10.1182/blood.V118.21.2888.2888
Published: 2011